Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy

Jeffrey A. Allen, Kenneth C. Gorson, Deborah Gelinas

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Introduction: We explored adherence to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) by reviewing data from a specialty pharmacy database. Materials and Methods: Clinical and electrophysiologic data were reviewed for 65 consecutive patients treated with intravenous immunoglobulin (IVIG) for CIDP. Three neuromuscular neurologists independently classified cases according to EFNS/PNS criteria as (1) fulfilling CIDP criteria; (2) non-CIDP (neither clinical nor electrophysiologic criteria met); or (3) unknown (insufficient information). Results: Patients were treated by 31 different community neurologists in 14 states. Only seven patients (11%) met clinical and electrodiagnostic CIDP criteria. The remainder (89%) did not have CIDP (49%) or were unknown (40%). IVIG mean induction dose was 1.25 g/kg, mean maintenance dose 0.79 g/kg, and mean interval between infusions was 23 days. Conclusions: Adherence to EFNS/PNS CIDP diagnostic and treatment guidelines in the general neurologic community was poor. Improved education and awareness of widely available CIDP guidelines are recommended.

Original languageEnglish (US)
Article numbere00932
JournalBrain and Behavior
Issue number3
StatePublished - Mar 2018

Bibliographical note

Publisher Copyright:
© 2018 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.


  • chronic inflammatory demyelinating polyneuropathy
  • clinical practice
  • diagnosis
  • guidelines
  • intravenous immunoglobulin


Dive into the research topics of 'Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy'. Together they form a unique fingerprint.

Cite this